Meningococcal Disease Guidelines
Vaccination Recommendations
All adolescents should receive MenACWY vaccine at age 11-12 years with a booster at age 16 years, while MenB vaccination for ages 16-23 years should be based on shared clinical decision-making 1.
Routine Vaccination Schedule by Age
Ages 11-23 years:
MenACWY (serogroups A, C, W, Y):
- Primary dose at 11-12 years
- Booster at 16 years (if first dose given before 16th birthday)
- Catch-up: Can vaccinate ages 19-21 if no dose received after 16th birthday
- College freshmen in residence halls need at least one dose within 5 years before entry
MenB (serogroup B):
- Ages 16-23 years based on shared clinical decision-making (preferred 16-18 years)
- Two-dose series: MenB-FHbp at 0 and 6 months, OR MenB-4C at 0 and ≥1 month
- Booster not routinely needed unless increased risk develops 1
Ages 2 months-10 years:
- Not routinely recommended except for high-risk groups 1
Ages ≥24 years:
- Not routinely recommended except for high-risk groups 1
High-Risk Populations Requiring Enhanced Vaccination
Certain individuals require a two-dose primary series of MenACWY (not just single dose) and repeated boosters 1:
- Persistent complement component deficiencies
- Complement inhibitor use (e.g., eculizumab)
- Anatomic or functional asplenia
- HIV infection
- Microbiologists routinely exposed to N. meningitidis
- Travel to hyperendemic areas
- Outbreak situations 1
Important caveat: MenB vaccines are only licensed for ages 10-25 years in the US, though off-label use may be considered for high-risk individuals ≥26 years 1.
Prophylaxis for Close Contacts
Ciprofloxacin is the preferred single-dose prophylaxis for close contacts, but alternative antibiotics should be used in areas with documented ciprofloxacin resistance 2, 3.
Antibiotic Prophylaxis Regimens
First-line: Ciprofloxacin (single dose)
- Adults: 500 mg once
- Children 5-12 years: 250 mg once
- Children <5 years: 30 mg/kg (max 125 mg) once 2
Alternative: Rifampicin (when ciprofloxacin contraindicated or resistance present)
- Age >12 years: 600 mg twice daily × 2 days
- Age 1-12 years: 10 mg/kg twice daily × 2 days
- Age <12 months: 5 mg/kg twice daily × 2 days 2
Other alternatives: Ceftriaxone or azithromycin 3
When to Switch from Ciprofloxacin
Health departments should preferentially use alternatives to ciprofloxacin when BOTH criteria are met in a 12-month rolling period:
- ≥2 invasive meningococcal disease cases caused by ciprofloxacin-resistant strains, AND
- ≥20% of all reported cases are ciprofloxacin-resistant 3
This is critical because ciprofloxacin-resistant strains have been increasing in the US since 2019, and prophylaxis failure with ciprofloxacin in these settings poses serious public health risk 3.
Who Qualifies as a Close Contact
- Household contacts within the previous 7 days
- Intimate kissing contacts
- Healthcare workers with direct exposure to respiratory secretions
- Childcare/nursery contacts in certain circumstances 2
Critical point: Prophylaxis should be initiated by public health authorities (CCDC/health protection teams), not by admitting clinicians 2.
Treatment of Acute Meningococcal Disease
Pre-Hospital Management
Antibiotics should be administered before hospital admission when meningococcal disease is suspected - this is a time-critical intervention that reduces mortality.
Notification Requirements
All cases of meningitis (regardless of etiology) must be notified to public health authorities - this is a legal obligation in the UK and US 2. Early contact with public health teams is essential for coordinating contact tracing and prophylaxis.
Vaccination of Index Cases
The index case should receive vaccination:
- Any unimmunized case <25 years should receive vaccination per national schedule
- Confirmed serogroup C cases previously immunized should receive MenC booster at discharge
- If ≥2 cases of serogroup B occur in same family, vaccinate all household contacts 2
Special Considerations
Emerging Resistance Patterns
Recent surveillance shows increasing ciprofloxacin resistance and re-emergence of the Hajj strain (serogroup W, ST-11), particularly associated with travel to Saudi Arabia 4. This underscores the importance of:
- Travel-related vaccination for pilgrims
- Ongoing antimicrobial susceptibility monitoring
- Flexible prophylaxis protocols 3, 4
Diagnostic Challenges
A significant proportion of patients receive antibiotics before specimen collection (44% before CSF collection, 31% before blood collection in one US study), which may lead to under-diagnosis of IMD 5. PCR testing should be utilized when antibiotics have been given pre-collection, though blood PCR is underutilized 5.
Atypical Presentations
Be alert for atypical presentations such as meningococcal epiglottitis (increasingly reported with serogroups W and Y), which may not present with classic meningitis symptoms 4.